Vireo Growth (VREOF) Other Non-Current Assets (2020 - 2026)
Vireo Growth's (VREOF) quarterly Other Non-Current Assets came in at $4.4 million in Q1 2026, up 944.53% year-on-year from $421244.0 in Q1 2025, and little changed quarter-over-quarter from $4.4 million in Q4 2025.
Vireo Growth (VREOF) Other Non-Current Assets (2020 - 2026) Analysis & Trends
Vireo Growth has disclosed Other Non-Current Assets across 7 years of filings, most recently posting $4.4 million for Q1 2026.
- Other Non-Current Assets for Q1 2026 came in at $4.4 million, up 944.53% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.4 million (up 944.53% YoY), and the FY2025 annual result was $4.4 million, up 944.53% from the prior year.
- Other Non-Current Assets came in at $4.4 million for Q1 2026 at Vireo Growth, roughly flat from $4.4 million in the prior quarter.
- In the past five years, Other Non-Current Assets ranged from a high of $8.6 million in Q2 2025 to a low of $383645.0 in Q2 2023.
- The 5-year median for Other Non-Current Assets is $593812.0 (2023), against an average of $1.9 million.
- Across the five-year window, Other Non-Current Assets tumbled 83.41% in 2023 and surged 1520.22% in 2025, its largest moves.
- Vireo Growth's Other Non-Current Assets stood at $2.3 million in 2022, then sank by 83.41% to $383645.0 in 2023, then rose by 9.8% to $421244.0 in 2024, then surged by 944.53% to $4.4 million in 2025, then changed by 0.0% to $4.4 million in 2026.
- The last three Other Non-Current Assets figures came in at $4.4 million (Q1 2026), $4.4 million (Q4 2025), and $2.1 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 1.79 Bn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 351.00 Mn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 233.20 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | 3.45 Mn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 73.60 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 295.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | 59.36 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | 47.63 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | - |
| 10 | Vireo Growth | - | - | 59.30 Mn | 4.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.40 Mn |
| Dec 31, 2025 | 4.40 Mn |
| Sep 30, 2025 | 2.13 Mn |
| Jun 30, 2025 | 8.65 Mn |
| Mar 31, 2025 | 421,244.00 |
| Dec 31, 2024 | 421,244.00 |
| Sep 30, 2024 | 533,745.00 |
| Jun 30, 2024 | 533,745.00 |
| Mar 31, 2024 | 533,745.00 |
| Dec 31, 2023 | 383,645.00 |
| Sep 30, 2023 | 383,645.00 |
| Jun 30, 2023 | 383,645.00 |
| Mar 31, 2023 | 593,812.00 |
| Dec 31, 2022 | 2.31 Mn |
| Sep 30, 2022 | 2.18 Mn |
| Jun 30, 2022 | 2.12 Mn |
| Mar 31, 2022 | 1.99 Mn |
| Dec 31, 2021 | 1.72 Mn |
| Sep 30, 2021 | 1.34 Mn |
| Jun 30, 2021 | 1.41 Mn |